Tacrolimus (Tacro) is a po tent immunosuppressant and a ce ntral agent in prevention of posttransplantation rejection. Tacro is characterized by a nar row therapeutic index and wide interindividual pharmacokinetic fluctuation. The contribution of human UDP-glucuronosyltransferase in its metabolism has not been extensively studied. In vitro metabolism studies support that the liver produced Tacro-glucuronide (Tacro-G) while its formation was minimal or undetectable in the presence of intestine and kidney microsomes. Among 17 human UGTs tested, UGT1A4 was the sole enzyme involved in Tacro-G formation. This conclusion is supported by the finding of inhibition with a specific substrate of UGT1A4 lamotrigine with K i values highly similar for b oth human liver and UGT1A4 microsomes and the correlation with trifluoperazine-glucuronide formation by liver microsomes (rs= 0.551; p=0.02). Formation of Tacro-G by liver samples was variable between individuals (6.4-fold variation; n=16) and common non-synonymous variants may contribute to this variability. In the HEK293 cellular model, no significant differences in e nzyme kinetics could be revealed for UGT1A4*2 (P 24 T) and * 3 (L 48 V) while the allozyme *4 (R 11 W) displayed a 2-fold higher velocity (p<0.01) compared to the UGT1A4*1 enzyme preparation. In human liver samples, carriers of the UGT1A4 variants did not display statistically different efficiency in Tacro-G formation compared to homozygote for the reference genotype UGT1A4*1/*1. We conclude that UGT1A4 is the major isoform involved in Tacro glucuronidation while additional studies are required to assess the contribution of UGT1A4 genetic factors in tacrolimus glucuronidation variability.
Introduction
Among factors involved in patient and graft survival following transplantation, immunosuppressant exposure and efficiency is cr itical in order to optimize clinical outcome. Immunosuppressive regimens in post-transplantation typically include a calcineurin inhibitor, cyclosporine or tacrolimus (Tacro), as w ell as o ther steroid and immune modulators such as mycophenolate mofetil and azathioprine, to name only a f ew. Tacro suppresses lymphocyte proliferation and interleukin synthesis, likely through a calcineurin-dependent inhibition of nuclear translocation and subsequent activation of nuclear factor of activated T cells transcription factors (Halloran, 2004) .
Because of the complex pharmacokinetics, pharmacodynamics, and pharmacogenetics of Tacro, the potential exists for adverse reactions and a high incidence of drug interactions. Tacro is characterized by a narrow therapeutic index and a large interindividual variation that would be explained, at least in part, by its metabolism. Tacro is metabolized by cytochromes P450 (CYP3A4 and CYP3A5) in both liver and small intestine and transported by P-glycoprotein (ABCB1) efflux transporter (Wallemacq et al., 2009) . Drugs that are substrates of these pathways, as well as inhibitors and inducers, can cause significant interactions with Tacro (Mertz et al., 2009 ). In addition, genetic variations in genes encoding for these proteins have been shown to interfere with Tacro pharmacokinetics, efficacy and toxicity (Kuypers et al., 2010; Staatz et al., 2010) . Tacro is also conjugated to glucuronide (-G) by the UDP-glucuronosyltransferase enzymes (UGTs) (Firdaous et al., 1997; Strassburg et al., 2001) . In support, Tacro-G is measured in human bile (Firdaous et al., 1997) . However, limited data are available with regards to the involvement of specific enzymes involved. In this study, we compared the glucuronidation activity for Tacro of major human metabolizing tissues; identified main UGT isozymes involve in the formation of Tacro-G and te sted common genetic variants in UGT1A4 coding regions. Inhaba (Trottier et al., 2010) . Human pooled colon and kidney microsomes were purchased from BD Gentest (Woburn, USA) and Celsis in vitro technologies (Chicago, IL, USA), respectively.
Glucuronidation assays.
Microsomal protein extracts from UGT1A-and UGT2B-overexpressing HEK cells, and tissues were prepared by differential centrifugation, quantified by western blot and assays conducted as described previously (Benoit-Biancamano et al., 2009 ). UGT1A4 first exon was amplified by PCR from each liver samples, and sequenced as described earlier (Benoit-Biancamano et al., 2009 ). The initial screening was performed for 16 hours with 200 μM Tacro at 37°C for liver, kidney, intestine microsomes and nine human UGT1A and seven UGT2B functionally active enzymes characterized to date (Fig.1) . Enzyme kinetics were then assessed in liver samples from individual donors and in one human intestine pool, as well as positive UGT, namely UGT1A4 reference protein *1 (R 11 P 24 L 48 ) as well as for its common variant alloenzymes *2 (T 24 ), *3 (V 48 ) and *4 (W 11 ). Assays were performed with Tacro ranging from 2 5 to 750 μM for 1 ho ur, while TFP assays were done according to the procedure described earlier (Court, 2005; Benoit-Biancamano et al., 2009 ). Inhibition constant (K i ) values were determined using Tacro (25-250μM), and AZT (0.1-2.5mM). The enzyme kinetic model was selected as described previously (Benoit- 
Results and Discussion
Glucuronidation of Tacro is exclusively performed by UGT1A4. Data reveals that T acro glucuronidation is formed by liver microsomes and to a lesser extent by intestine proteins, consistent with a previous report (Strassburg et al., 2001 ). In the presence of recombinant human UGT proteins, Tacro-G detected by mass spectrometry, was found exclusively for UGT1A4 (Fig.1C ). This contrasts with a pr evious study that identified UGT2B7 as the major UGT enzyme involved in T acro-G formation based on enzymatic assays using microsomal protein extracts from Sf9 cells infected with UGT-recombinant baculovirus and d etection of t he glucuronide product by thin layer chromatography (Strassburg et al., 2001 ).
Evidence against a role of UGT2B7 in Tacro-G formation is the absence of its glucuronidation by UGT2B7-HEK293 microsomes and by a commercial preparation of UGT2B7 recombinant proteins, both positive for the glucuronidation of a U GT2B7 substrate, AZT (data not shown). In addition, Tacro-G remained undetectable in the presence of human kidney microsomes that express abundantly UGT2B7 but not UGT1A4 (Fig.1C ) (Ohno and Nakajin, 2009) . A role for UGT2B7 in Tacro-G formation is likely not significant and this reaction would be performed exclusively by UGT1A4.
Data from competitive assays performed with liver and UGT1A4-HEK293 microsomes using specific substrates LTG for UGT1A4 and AZT for UGT2B7 (Court, 2005) , also sustain this conclusion.
Tacro-G formation was influenced in a concentration-dependent manner by LTG for both liver and UGT1A4 -derived proteins but not in the presence of AZT. Furthermore, the apparent K i values estimated for inhibition of Tacro glucuronidation by LTG were almost identical in liver and UGT1A4
(0.43 ± 0.26 and 0.47 ± 0.28mM, respectively) in support of t he involvement of t his sole enzyme (Fig.2) . Another observation is the affinity of UGT1A4 that appears higher for Tacro compared to Tacro-G formation rates compared to the reference UGT1A4*1 protein (3.14 ± 0.51 for *4 vs. 1.65 ± 0.34 for *1; p=0.007), resulting in a 67% increased in the ratio V max /K m for UGT1A4*4. It remains to be determined if UGT1A4*4 could possibly result in a lower tacrolimus exposure in vivo. No significant changes of T acro-G formation could be revealed for U GT1A4*2 and UGT1A4*3 allozymes whereas significant alteration of enzyme kinetics for other substrates has been reported previously, suggesting a substrate specific effect of these coding variations (Ehmer et al., 2004; Benoit-Biancamano et al., 2009 ). Formation of Tacro-G by 16 l iver samples further supports variability between individuals (0.16 -1.03 area/min/mg; 6.4-fold variation). Kinetic parameters of homozygote carriers of UGT1A4*1 (n=2), and heterozygotes UGT1A4*1/*2 (n=2) or UGT1A4*1/*3 (n=2) was also assessed, while no individual with the UGT1A4*4 allele could be tested because of its low frequency ( Table 1) . Rates of Tacro-G formation between *1/*1 carriers was highly similar Harvey, É. Lévesque and C. Guillemette.
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